NICE
Regimen
- Experimental
- neoadjuvant nab-paclitaxel + carboplatin + camrelizumab x2
Population
Clinical N2-3 ESCC (high nodal burden), resectable
Key finding
2y OS 78.1%; 2y RFS 67.9%; MPR strongly prognostic (2y OS 91% vs 48%); distant metastasis dominant recurrence pattern.
Source: PMID 37696429